Lomond Therapeutics Holdings Files Q2 2025 10-Q
| Field | Detail |
|---|---|
| Company | Lomond Therapeutics Holdings, Inc. |
| Form Type | 10-Q |
| Filed Date | Aug 14, 2025 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, SEC-filing
TL;DR
Lomond Therapeutics (LMTX) filed its Q2 2025 10-Q. All systems go.
AI Summary
Lomond Therapeutics Holdings, Inc. filed its quarterly report for the period ended June 30, 2025. The company, formerly known as Venetian-1 Acquisition Corp., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located in Dover, Delaware.
Why It Matters
This filing provides investors with an update on Lomond Therapeutics' financial performance and operational status for the second quarter of 2025.
Risk Assessment
Risk Level: low — This is a standard quarterly filing providing routine financial and operational updates.
Key Numbers
- 000-56377 — Commission file number (Identifies the company's filing with the SEC)
- 87-2959575 — I.R.S. Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Lomond Therapeutics Holdings, Inc. (company) — Registrant
- June 30, 2025 (date) — Quarterly period end date
- Venetian-1 Acquisition Corp. (company) — Former company name
- Delaware (location) — State of incorporation and principal executive offices
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What is the primary business of Lomond Therapeutics Holdings, Inc.?
Lomond Therapeutics Holdings, Inc. operates in the Pharmaceutical Preparations sector, as indicated by its Standard Industrial Classification code 2834.
When was the company formerly known as?
The company was formerly known as Venetian-1 Acquisition Corp., with a date of name change on December 20, 2021.
Where are Lomond Therapeutics Holdings, Inc.'s principal executive offices located?
The principal executive offices are located at 8 The Green Ste 8490, Dover, Delaware, 19901.
What period does this 10-Q filing cover?
This Form 10-Q is a quarterly report for the period ended June 30, 2025.
What is the company's state of incorporation?
The company is incorporated in Delaware.
Filing Stats: 4,421 words · 18 min read · ~15 pages · Grade level 19.9 · Accepted 2025-08-14 16:33:26
Key Financial Figures
- $0.0001 — ange on Which Registered Common Stock, $0.0001 par value per share N/A N/A Indicate
Filing Documents
- ea0252677-10q_lomond.htm (10-Q) — 703KB
- ea025267701ex31-1_lomond.htm (EX-31.1) — 11KB
- ea025267701ex31-2_lomond.htm (EX-31.2) — 11KB
- ea025267701ex32-1_lomond.htm (EX-32.1) — 11KB
- 0001213900-25-076735.txt ( ) — 3921KB
- cik0001900520-20250630.xsd (EX-101.SCH) — 31KB
- cik0001900520-20250630_cal.xml (EX-101.CAL) — 23KB
- cik0001900520-20250630_def.xml (EX-101.DEF) — 186KB
- cik0001900520-20250630_lab.xml (EX-101.LAB) — 323KB
- cik0001900520-20250630_pre.xml (EX-101.PRE) — 193KB
- ea0252677-10q_lomond_htm.xml (XML) — 363KB
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations 2 Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) 3 Condensed Consolidated Statements of Cash Flows 5 Notes to Condensed Consolidated Financial Statements 6 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 32 Item 4.
Controls and Procedures
Controls and Procedures 32
- OTHER INFORMATION
PART II - OTHER INFORMATION 33 Item 1.
Legal Proceedings
Legal Proceedings 33 Item 1A.
Risk Factors
Risk Factors 33 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 33 Item 3. Defaults Upon Senior Securities 33 Item 4. Mine Safety Disclosures 33 Item 5. Other Information 33 Item 6. Exhibits 34
Signatures
Signatures 35 i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION CONTAINED IN THIS REPORT This Quarterly Report, including the sections entitled " Risk Factors " and " Management's Discussion and Analysis of Financial Condition and Results of Operations , " includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements relate to, among others, our plans, objectives and expectations for our business, operations and financial performance and condition, and can be identified by terminology such as "may," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "will," "could," "project," "target," "potential," "continue" and similar expressions that do not relate solely to historical matters. Forward-looking that the expectations reflected in forward-looking statements are reasonable, such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. Forward-looking the ability of our preclinical studies and future clinical trials to demonstrate safety and efficacy of product candidates that we may develop, license or acquire and other positive results; any action we may take in the future with respect to our related party license agreements with Eil Therapeutics, Inc., or Eil, and Bala Therapeutics, Inc., or Bala, including our ability to meet repayment obligations under promissory note